Skip to main content

Systems prediction of Chronic Lung Allograft Dysfunction

Ziel

Lung transplantation (LT) is the standard of care for selected patients with chronic respiratory failure. Chronic lung allograft dysfunction (CLAD) (i.e. “Bronchiolitis obliterans syndrome” (BOS) and “Restrictive Allograft Syndrome” (RAS)) represents a major health risk for LT recipients, requiring the use of heavy treatments and possible retransplantation. Observed in almost 50% of patients after 5 years post LT, it is currently impossible to predict the appearance of CLAD before the onset of first symptoms. This project aims to develop the SysCLAD model which will allow to predict, within the 1st year post LT, the recipients at risk of developing CLAD by 3 years post LT. Building upon available data from the cohort of lung transplantation (COLT, recruited since mid-2009), this project will integrate new LT recipients to form the European cohort of lung transplantation (ECOLT). The SysCLAD prediction tool will be based on a mathematical model developed through a system biology approach integrating both clinical and biological data collected from a total of 400 LT recipients. The model will be validated on the first 200 LT recipients (3 years follow-up at project start) and refined using the new set of 200 LT data with 3 years follow-up by 2014. The aim is to identify and validate the signature of CLAD both at the clinical and molecular levels to allow for an early recognition and specific interventions in patients at risk of CLAD. The implementation of the model is expected to significantly improve the cost-effectiveness of post-LT treatments, limit the risk of graft rejection in LT recipients and, ultimately lead to an improved quality of life and a prolonged life expectancy of patients following LT. Finally, the SysCLAD model holds further great promises in the context of other chronic bronchial inflammatory diseases of major incidence such as severe asthma and Chronic Obstructive Pulmonary Disease (COPD) to predict decline in lung function.

Aufforderung zur Vorschlagseinreichung

FP7-HEALTH-2012-INNOVATION-1
Andere Projekte für diesen Aufruf anzeigen

Koordinator

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
Adresse
Rue Du Bugnon 21
1011 Lausanne
Schweiz

Auf der Karte ansehen

Aktivitätstyp
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Kontakt Verwaltung
Thuy Oetli (Ms.)
EU-Beitrag
€ 454 400,50

Beteiligte (8)

UNIVERSITE JOSEPH FOURIER GRENOBLE 1
Frankreich
EU-Beitrag
€ 522 200
Adresse
Avenue Centrale, Domaine Universitaire 621
38041 Grenoble

Auf der Karte ansehen

Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Yann Leroux (Mr.)
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
Frankreich
EU-Beitrag
€ 848 700
Adresse
Allee De L'ile Gloriette 5
44093 Nantes

Auf der Karte ansehen

Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Karine Botturi-Cavaillès (Ms.)
NOVADISCOVERY
Frankreich
EU-Beitrag
€ 346 970
Adresse
1 Place Giovanni Da Verrazzano
69009 Lyon

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
François-Henri Boissel (Mr.)
BIOMAX INFORMATICS AG
Deutschland
EU-Beitrag
€ 243 765,75
Adresse
Robert Koch Strasse 2
82152 Planegg

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Dieter Maier (Dr.)
Eurofins Genomics Europe Sequencing GmbH
Deutschland
EU-Beitrag
€ 416 616
Adresse
Jakob Stadler Platz 7
78467 Konstanz

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Janet Kenklies (Dr.)
FINOVATIS
Frankreich
EU-Beitrag
€ 101 000
Adresse
62 Rue De Bonnel
69003 Lyon

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
David Koubi (Dr.)
University of Zurich
Schweiz
EU-Beitrag
€ 37 500
Adresse
Ramistrasse 71
8006 Zurich

Auf der Karte ansehen

Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Andreas Ledergerber (Mr.)
HLA ET MEDECINE
Frankreich
EU-Beitrag
€ 27 999,75
Adresse
Avenue Claude Vellefaux 1
75010 Paris

Auf der Karte ansehen

Aktivitätstyp
Research Organisations
Kontakt Verwaltung
Charles Auffray (Dr.)